Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Corporate Fact Sheet Overview Luminex® Corporation (NASDAQ: LMNX) develops, manufactures and markets a proprietary technology with applications throughout the life-sciences industry, including clinical diagnostics. This industry depends on a broad range of tests, known as “bioassays,” to discover new drugs, identify new biological pathways or assist in diagnosis and/or monitoring of diseases. The in-house experts at Luminex have developed an innovative approach to bioassays, known as xMAP® Technology. This groundbreaking technology enables laboratories to multiplex bioassays, reducing time, labor, and costs over traditional methods. Luminex has been marketing the current generation of xMAP Technology (formerly known as LabMAP®) worldwide since 1999. Due to its openarchitecture platform, xMAP Technology can be applied across a wide range of markets. In fact, xMAP Technology-based systems are already in use by leading clinical diagnostics and research laboratories as well as major pharmaceutical and biotechnology companies. Escalating R&D spending, the evolution of disease specific test panels, and the evolution of pharmacogenomics are fueling the growth of the drug discovery, clinical diagnostics and biomedical research markets — including both genomics and proteomics research. With this expansion of market opportunities, Luminex is strategically positioned for sustained growth and success. Highlights • Luminex develops an innovative biological testing technology that delivers competitive advantages in speed, precision, flexibility and cost • Luminex offers an open-ended and broadly enabling technology that’s already validated by prominent customers worldwide • Assay topic to come • Luminex addresses a large global market in which xMAP technology is poised to become the industry standard • Luminex expects to generate multiple, recurring revenue streams via: • Sales of instrumentation • Sales of proprietary testing consumables known as xMAP microspheres • Royalties on products and tests developed for use with xMAP technology Luminex Assay Groups Luminex Bioscience Group The Luminex Bioscience Group, Inc., was established in late 2005 to develop and commercialize customer-driven xMAP-based assays for channel partners and end-user customers in key market segments. Luminex Molecular Diagnostics Luminex Molecular Diagnostics was formed in March 2007 when Luminex acquired Tm Bioscience of Toronto, Canada. This division of Luminex Corporation specializes in DNA-based research and diagnostics and is focused specifically on the design, development, manufacture, and commercialization of nucleic-acid based testing products for genetic testing, personalized medicine and infectious disease. Market Opportunity As of 2007, Luminex estimated that the combined market for bioassays within its key market segments to be approximately $3.8 billion. The life sciences industry uses bioassays to detect the presence of certain biochemicals, proteins or genes in a sample. These types of tests are used extensively in drug discovery, genetic analysis, pharmacogenomics, clinical diagnostics and general biomedical research. While other bioassay technologies are available in each of these areas, xMAP Technology from Luminex is flexible enough to be applied to all. Each of these markets represents a significant opportunity for Luminex due to: • Increased R&D spending by pharmaceutical and biotechnology companies • A shift in R&D focus from discovery to functional genomics and proteomics • An increase in disease targets due to the success of drug discovery efforts • Evolution of pharmacogenomics and increased demand for SNP (single nucleotide polymorphism) studies • The evolution of disease-specific test panels Proprietary Technology Luminex’s xMAP Technology is built on proven technology – flow cytometry, microspheres, lasers, digital signal processing and traditional chemistry – that have been combined in a unique way. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. The analyzer reads multiplexed assay results The Luminex 100/200 System uses powerful, flexible xMAP Technology to perform up to 100 bioassays at a time. by identifying color differences between the beads as well as the presence or absence of a fluorescent reporter marker, all done in real time. And thanks to its flexible, open-architecture design, xMAP Technology can be configured to perform a wide variety of bioassays quickly, cost-effectively and accurately. Business Strategy In order to establish xMAP technology as the industry standard for performing bioassays, Luminex is carrying out strategic plans to: • Focus on large, fast-growing segments of the life-sciences industry — including major pharmaceutical companies, large clinical companies and laboratories, in-vitro diagnostic manufacturers, and major medical institutions • Forge key partnerships to broaden and accelerate market acceptance of xMAP Technology • Enable partners to design their own tests using our open-ended technology, thereby encouraging the expansion of bioassay development and providing additional competitive advantages • Expand the functionality of the xMAP Technology-based product line Key Growth Strategies • Enhance technology leadership with future generations of xMAP Technology, expanding its multiple testing capabilities and increasing throughput • Participate in the $20 billion clinical diagnostics market by providing FDA compliant xMAP Technology • Convince prospective partners and customers that xMAP Technology is an attractive alternative to other approaches • Manufacture products in sufficient quantities with acceptable quality and cost • Place and service sufficient quantities of our products Products Consumables Management Team Luminex® 100/200™ The Luminex 100/200 System is a compact analyzer that performs up to 100 bioassays simultaneously, using a single drop of fluid – therefore requiring very small patient samples when compared with other testing technologies. This system utilizes xPONENT and IS 2.3 software. The Luminex 100/200 and diagnostic kits developed by Luminex strategic partners have received 510(k) clearance from the FDA and can be used on the Luminex 100/200 system for diagnostic purposes. Luminex® MicroPlex™ Microspheres MicroPlex Microspheres (formerly named Multi-Analyte Microspheres) are internally labeled with fluorescent dyes and are available with either carboxylate or avidin surface chemistries. Patrick J. Balthrop Sr., President and Chief Executive Officer Russell W. Bradley, Vice President, Business Development and Strategic Planning Jeremy Bridge-Cook, Ph.D. Vice President, Luminex Molecular Diagnostics Douglas C. Bryant, Executive Vice President and Chief Operating Officer John C. Carrano, Ph.D., Vice President, Research and Development Harriss T. Currie, Vice President, Finance and Treasurer Chief Financial Officer Andy Ewing, Vice President, Technical Operations Gregory J. Gosch, Vice President, Luminex Bioscience Group Darin S. Leigh, Vice President, Sales and Marketing Randel S. Marfin, Vice President, Strategic Development Oliver H. Meek, Vice President, Quality Assurance and Regulatory Affairs David S. Reiter, Vice President, General Counsel and Corporate Secretary Stephen Back, Vice President, Manufacturing xPONENT® Software Solutions xPONENT software brings the power of integration and automation to laboratories and improves workflow efficiency. xPONENT software combines ease of use and flexibility to perform both protein and nucleic acid testing on one Luminex system. Assays Luminex has identified key assay development opportunities as a response to the market demand for multiplexed solutions in emerging bio-assay applications, providing effective solutions to partners and customers. microRNA Assays FlexmiRTM Select FlexmiRTM Human Panel FlexmiRTM Mouse/Rat Extension Panel FlexmiRTM Labeling Kit FlexmiRTM Reagent Pak FlexmiRTM Control Panel Molecular Diagnostics Assays CFTR IVD xTAGTM RVP Ashkenazi Jewish Panel* CFTR 70+6* Coagulation Panel* P450-2C19* P450-2C9* P450-2D6* P450-2C9+VKORC1* *For Investigational Use Only. The performance characteristics of this product have not been established. UNITED STATES Luminex Corporation 12212 Technology Blvd. Austin, Texas 78727 United States Tel: 512.219.8020 Fax: 512.219.5195 CANADA Luminex Molecular Diagnostics 439 University Ave, Suite 900 Toronto, ON M5G 1Y8 Canada Tel: 416.593.4323 Fax: 416.593.1066 Luminex® MagPlex™-C Microspheres MagPlex-C Microspheres are superparamagnetic carboxylated xMAP microspheres internally labeled with fluorescent dyes. Magnetic separation offers the best enablement of automation, eases samples preparation and obviates the need for costly filter plates. Luminex® xTAG™ Microspheres xTAG Microspheres (formerly FlexMAP Microspheres) are pre-coupled with universal oligonucleotides, optimized for isothermal multiplexing (up to 100-plex) with minimal crosstalk. Capture conditions are therefore standardized and independent of content-specific reactions, allowing ultimate flexibility in assay design. Partners Luminex has more than 50 partners in the pharmaceutical drug discovery, clinical diagnostics and biomedical research markets. They include: • Abbott Molecular • ARUP • Asuragen • Bio-Rad • BMD • Caymen Chemical • Cogenics • Celera Diagnostics • Charles River Laboratories • EMD Chemicals/Merck • EraGen Biosciences • Expression Analysis • Fisher Healthcare • Focus Diagnostics • Innogenetics NV • Immunetech • INOVA Diagnostics • Inverness Medical Professional Diagnostics • Invitrogen Corporation • Marligen • Millipore • MiraiBio • One Lambda • Panomics, Inc. • PerkinElmer, Inc. • QIAGEN, Inc. • R&D Systems • Radix Biosolutions • Rules Based Medicine • Tepnel Lifecodes • Zeus Scientific EUROPE Luminex B.V. Krombraak 15 4906 CR Oosterhout The Netherlands Tel: +31.162.408333 Fax: +31.162.408337 Investor Highlights Headquarters: Austin, Texas Founded: 1995 IPO Date: March 30, 2000 Nasdaq® Symbol: LMNX Research Coverage: America’s Growth Capital Avondale Partners Cannacord Adams GARP Research & Securities Jesup & Lamont Securities Corporation Leerink Swann Lehman Brothers Pacific Growth Equities Thomas Weisel Partners Shares Outstanding at 3/31/08: Approx. 36.7 Million Contact Information Luminex Corporation - Headquarters 12212 Technology Blvd. Austin, TX 78727 Tel. 512.219.8020 Toll Free 888.219.8020 (in North America) Fax 512.219.6325 www.luminexcorp.com [email protected] [email protected] Statements made herein that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events that are forward-looking statements. These words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will” and similar expressions are intended to further identify such forward-looking statements. It in important to note that the company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, market demand and acceptance of Luminex’s products, the company’s dependence on strategic partners for development, commercialization and distribution of products, competition, Luminex’s ability to scaleup manufacturing operations, potential shortages of components and the timing of regulatory approvals, as well as the risks discussed under the heading “Factors That may Affect Future Results” in Luminex’s Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this release, and Luminex expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. www.luminexcorp.com [email protected] [email protected] © 2008 Luminex Corporation. xMAP, Luminex 100, Luminex 200, Luminex HTS, xTAG, MicroPlex, FlexmiR, MagPlex and xPONENT are trademarks of Luminex Corporation. Specifications and features subject to change without notice. 070808-080-01